


Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia

SUPPLEMENTARY FIGURE



Supplementary Figure S1: Evaluation of cytotoxic effect in response to Ibrutinib/RG7112 combination in B leukemic cell lines. The p53^{wild-type} EHEB and the p53^{mutated} MEC-2 leukemic cells as well as cells of a representative B-CLL patient (Pt.) sample were exposed to Ibrutinib (10 μ M) and RG7112 (10 μ M) used either alone or in combination for 48 hours. Cell viability was calculated as percentage with respect to the control untreated cultures (set to 100% for each cell culture). Data are reported as the mean \pm SD of results from at least three independent experiments. The asterisk indicates $p < 0.05$ respect to single treatments.